Immunomedics, Inc. (IMMU) Reports Preclinical Results On SN-38 Antibody-Drug Conjugates As A Potential Novel Platform For Treating Cancer
4/8/2014 7:29:17 AM
SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported results from preclinical studies on the Company's two investigational SN-38-containing antibody drug conjugates (ADCs), IMMU-130 and IMMU-132, that demonstrated a high therapeutic index for both agents.
Help employers find you! Check out all the jobs and post your resume.
comments powered by